|Bid||13.74 x 1000|
|Ask||13.76 x 1000|
|Day's Range||13.65 - 14.39|
|52 Week Range||6.00 - 14.91|
|Beta (3Y Monthly)||1.66|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.00|
MENLO PARK, Calif., March 19, 2019 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.
Dermira Inc NASDAQ/NGS:DERMView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing Bearish sentimentShort interest | NeutralShort interest is moderate for DERM with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on March 4. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding DERM are favorable, with net inflows of $1.41 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it intends to offer $110.0 million of its common stock in an underwritten public offering. Dermira also expects to grant to the underwriters a 30-day option to purchase up to an additional $16.5 million of its common stock in the offering. All of the shares will be offered and sold by Dermira. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Citigroup, Cowen, Cantor Fitzgerald & Co. and Guggenheim Securities are acting as book-runners for the offering.
Why Dermira Stock Is Soaring More than 80% TodayShare price movements Today, Dermira (DERM) is trading close to $12.85, ~87.87% higher than its previous closing price, with a market capitalization of $292.48 million. The company is trading 114.19%
Boeing shares slipped more than 1.5 percent after The Wall Street Journal reported that federal prosecutors and the Department of Transportation are scrutinizing the development of the company's 737 Max jets. An Ethiopian Airlines flight involving the 737 Max 8 crashed on March 10. Facebook FB — Shares of the social media giant fell more than 3 percent after an analyst at Needham downgraded them to hold from buy.
Dermira news concerning results from a recent Phase 2b study has DERM stock flying high on Monday.Source: DermiraDermira (NASDAQ:DERM) is reporting that results from its Phase 2b study of using lebrikizumab to treat patients with atopic dermatitis were positive. Atopic dermatitis is a type of skin condition that's main symptom is a red, itchy rash.The Dermira news includes the results from the company testing out three different dosage amounts of lebrikizumab in adult patients with moderate-to-severe atopic dermatitis. All three of these dosage levels were able to meet the primary endpoints of the Phase 2b study.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe Phase 2b study of lebrikizumab involved 280 patients that were 18 or older. These patients were split into four groups for the study. Three of these groups received lebrikizumab at different amounts and the fourth was the placebo group. The treatment was also well tolerated with only mild to moderate adverse events."I have many patients for whom current therapies do not adequately address their needs," Emma Guttman-Yassky, M.D., Ph.D., and a leading investigator in the study, said in a statement . "These data show that lebrikizumab may offer a targeted, effective and well-tolerated therapeutic approach." * 7 Small-Cap Stocks That Make the Grade The positive Dermira news from the Phase 2b study results means that the company is planning to move forward with a Phase 3 study of the drug. It plans to start this next study quickly after getting in contact with U.S. regulators.DERM stock was up 83% as of noon Monday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 of the Best Stocks to Buy Under $10 * 7 Single-Digit P/E Stocks With Massive Upside * 7 Best Quantum Computing Stocks Trading Today As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Dermira News: Why DERM Stock Is Skyrocketing Today appeared first on InvestorPlace.
The stock surged as much as 118 percent on Monday, the most ever, after data showed that its experimental therapy for atopic dermatitis, or eczema, demonstrated results that were better than Regeneron Pharmaceuticals and Sanofi’s star drug Dupixent. Regeneron shares fell 1 percent. Dupixent is forecast to generate $4.65 billion in sales by 2022, overtaking Eylea as the company’s largest drug, according to estimates compiled by Bloomberg.
shares more than doubled Monday after the group said its new eczema treatment passed a key study in adult patients with moderate-to-severe atopic dermatitis. Dermira, which acquired the development rights to lebrikizumab, from which the treatment is based, from Swiss pharma giant Roche in 2016, said all three doses of lebrikzumab met the primary endpoint with statistical significant in the phase II study. Dermira could use the results to launch a sustained challenger into the global market for atopic dermatitis treatments, which analysts estimate could hit $7.66 billion by 2021.
Dermira reported positive results ahead of the market open Monday from a Phase 2b dose-ranging study of lebrikizumab that is being evaluated for treating adult patients with moderate-to-severe atopic dermatitis. Lebrikizumab is a humanized antibody that binds interleukin-13, or IL-3, inhibiting downstream signaling. Dermira said all three doses evaluated in the dose-ranging study — 125mg every four weeks, 250mg every four weeks and 250mg every two weeks — met the primary endpoint of showing greater improvements in the Eczema Area and Severity, or EASI, index at week 16 compared to placebo.
Dermira Inc. shares soared 83% in premarket trade Monday, after the biotech reported positive results in a mid-stage trial of a treatment for moderate-to-severe atopic dermatitis. The Menlo Park, Calif.-based company said a phase 2b trial of Lebrikizumab met its primary endpoint of demonstrating greater improvements in the Eczema Area and Severity Index score (EASI) compared to placebo. The safety profile was consistent with prior studies. Lebrikizumab is an injectable, humanized monoclonal antibody that's designed to specifically block the action of interleukin-13, or IL-13, a substance secreted by certain cells of the immune system that is a central pathogenic mediator in atopic dermatitis. The study involved 280 patients. Atopic dermatitis is a common and severe form of eczema characterized by rashes on the skin that can cover much of the body and include redness, cracking, dryness and intense itching. Dermira shares have fallen 24.8% in the last 12 months, while the S&P 500 has gained 2.6%.
Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced positive results from a Phase 2b dose-ranging study of lebrikizumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis. All three doses of lebrikizumab met the primary endpoint, demonstrating greater improvements in the Eczema Area and Severity Index (EASI) score compared to placebo. The safety profile for lebrikizumab observed in the study was consistent with prior studies evaluating this investigational therapy.
MENLO PARK, Calif., March 05, 2019 -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering.
Three poster presentations from Phase 3 glycopyrronium tosylate clinical program address clinically relevant questions impacting people living with primary axillary.
QBREXZA™ (glycopyrronium) cloth 2018 net product sales of $3.0 millionOver 14,500 prescriptions for QBREXZA written in first three months of launchSecured QBREXZA coverage for.
NEW YORK, NY / ACCESSWIRE / February 26, 2019 / Dermira Inc (NASDAQ: DERM ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 26, 2019 at 4:30 PM Eastern ...
Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced that new post-hoc analyses from its glycopyrronium tosylate (QBREXZA™ (glycopyrronium) cloth) clinical program will be presented in poster format at the 77th Annual Meeting of the American Academy of Dermatology (AAD) being held in Washington, D.C., March 1-5, 2019. Poster presentations will highlight post-hoc data analyses from the Phase 3 clinical trials evaluating glycopyrronium tosylate in patients 9 years and older with primary axillary hyperhidrosis, commonly referred to as excessive underarm sweating.
Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, announced today the initiation of a proof-of-concept study that will evaluate the efficacy and safety of QBREXZA™ (glycopyrronium) cloth in people living with primary palmar hyperhidrosis (excessive sweating of the hands). QBREXZA is a once-daily, prescription anticholinergic that was approved by the U.S. Food and Drug Administration (FDA) to treat adult and pediatric patients 9 years of age and older living with primary axillary hyperhidrosis, a medical condition commonly referred to as excessive underarm sweating.